A panelist discusses how prurigo nodularis is a chronic inflammatory skin condition that disproportionately affects middle-aged adults and those with immune disorders, causing intensely pruritic nodules that significantly impact quality of life through both physical discomfort and psychological distress.
A panelist discusses how the treatment landscape for prurigo nodularis (PN) has evolved from primarily using topical therapies and off-label systemic medications to incorporating FDA-approved targeted biologics such as dupilumab and nemolizumab, which have demonstrated significant efficacy in reducing both the itchiness and nodular lesions.
A panelist discusses how diagnostic differentiation of prurigo nodularis requires careful examination of the characteristic firm, hyperkeratotic nodules and consideration of the patient's history of chronic pruritus and scratching behavior, while noting that comorbid atopic dermatitis may influence treatment selection toward dual-targeting therapies.
A panelist discusses how this patient's history of chronic kidney disease, diabetes, and psychological stress are significant contributing factors to his prurigo nodularis, necessitating a comprehensive treatment approach that addresses both the underlying conditions and the itch-scratch cycle.
A panelist discusses how the advent of targeted systemic therapies such as dupilumab and nemolizumab has transformed the treatment landscape for prurigo nodularis, offering more effective options for breaking the itch-scratch cycle while maintaining favorable safety profiles compared with traditional systemic treatments.
